This activity is particularly notable in select NSCLC patients with asymptomatic BMs and high Programmed Death-Ligand 1 (PD-L1) expression.<h4>Conclusions</h4>More research is needed to fully understand the efficacy of ICIs in treating BMs. The gene discussed is CD274; the disease is non-small cell lung carcinoma.